Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy skies hovering over the Pharmalot campus. After all, as the Morning Mayor used to say: Every brand new day should be unwrapped like a precious gift. Toward that end, we are celebrating as our shortest person turns another page on the calendar of life. This calls for a few cups of stimulation. Our choice today is Jack Daniel’s. Yes, this is real. Meanwhile, here are a few items of interest. Hope you have a smashing day and do keep in touch …

A controversial treatment for preventing premature births will be reviewed by an FDA panel on Tuesday amid intensifying debate over whether the medication, called Makena, should remain on the market, STAT says. The panel is set to review a required followup study that found the medicine was not effective, a troublesome development given that Makena is the standard of care. The results called into question the extent to which physicians should continue to use the medicine and prompted intense betting on Wall Street about what the FDA will do.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy